Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
Kelsey W. Nassar(University of Colorado Anschutz Medical Campus), Rebecca E. Schweppe(University of Colorado Cancer Center)
Cited by 37
Related Papers
Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer
|The Journal of Clinical Endocrinology & Metabolism|2009|65
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies
|Cancer Biology & Therapy|2024|7